|
| |
| VIOXX Recalls |
| |
VIOXX is pulled from the market due to safety concerns of an
increased risk of heart attack and other serious health problems
Merck & Co., Inc. announced a voluntary withdrawal of Vioxx (rofecoxib)
from the U.S. and worldwide market due to safety concerns of an
increased risk of cardiovascular events (including heart attack
and stroke) in patients on Vioxx. Merck obtained FDA approval on
Vioxx in approximately April 1999 via a New Drug Application on
a fast-track, 6-month approval process. Merck began distribution
and sale of Vioxx throughout the United States in approximately
May 1999 for the relief of the signs and symptoms of
osteoarthritis, for the management of acute pain in adults, and
for the treatment of menstrual symptoms. Vioxx was later
approved for the relief of the signs and symptoms of rheumatoid
arthritis in adults and children.
Tim Ryan is at the forefront of Vioxx litigation, representing
injured victims and families whose lives have been adversely
affected by Vioxx-related illnesses. If you have additional
questions or concerns about Vioxx® or if you have suffered as
the result of taking Vioxx, please
contact Tim Ryan and
Associates immediately to discuss your case. We are
currently investigating these cases and would be pleased to
evaluate your case.
As always, there is NO FEE for this consultation. |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
| |
|
|
| |
 |
| |
 |
 |
 |
 |
FREE subscription
Fill in the form below with your email and get access to our
Newsletters for FREE !! |
|
 |
 |
|
 |
|
|
